Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials
Authors:
- Chandra F MeghrajaniCMChandra F Meghrajani
- Clarita C MaanoCMClarita C Maano
- 10 January 2012
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 5 (1) , 91-97
Abstract
Seborrheic dermatitis is a common, chronic, relapsing inflammatory skin disorder that manifests as erythema, scaling and pruritus in sebum gland-rich areas of the skin. The objective of this article is to evaluate the clinical efficacy of pimecrolimus 1% cream in the treatment of seborrheic dermatitis compared with corticosteroids, antimycotics, placebo or no intervention. Pimecrolimus 1% cream appears to be a well-tolerated and effective treatment for seborrheic dermatitis. It has comparable efficacy, in terms of decreasing severity of erythema, scaling and pruritus, to the standard treatments: topical corticosteroids and antimycotics. However, future studies with more standardized measures of treatment outcome are recommended. More studies may also be conducted to further evaluate pimecrolimus 1% cream as a long-term maintenance therapy for seborrheic dermatitis.Keywords
This publication has 17 references indexed in Scilit:
- Experience with repetitive use of pimecrolimus: Exploring the effective and safe use in the treatment of relapsing seborrheic dermatitisJournal of Dermatological Treatment, 2009
- An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitisJournal of Dermatological Treatment, 2009
- Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: A randomized clinical studyJournal of Dermatological Treatment, 2009
- Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitisJournal of the American Academy of Dermatology, 2007
- Treatment of Facial Seborrheic Dermatitis with Pimecrolimus Cream 1%: An Open-Label Clinical Study in Korean PatientsJournal of Korean Medical Science, 2007
- A New Calcineurin Inhibitor, Pimecrolimus, Inhibits the Growth of Malassezia sppAntimicrobial Agents and Chemotherapy, 2006
- Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentationJournal of the American Academy of Dermatology, 2006
- Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trialBritish Journal of Dermatology, 2004
- Etiology and Management of Seborrheic DermatitisDermatology, 2004
- Pimecrolimus: A reviewJournal of the European Academy of Dermatology and Venereology, 2003